Tuesday July 21, 11:46 am Eastern Time
Company Press Release
SOURCE: Advanced Viral Research Corp.
Advanced Viral Research Corp. Announces Approval by Mexico for Trial of Reticulose
in AIDS
YONKERS, N.Y., July 21 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - news) today announced that its
lead immunomodulator drug, Reticulose, has been approved for human clinical trial in Mexico. The double blind placebo controlled study
will evaluate the effectiveness of Reticulose in combination with three ''cocktail type'' AIDS drugs for treatment of adults infected with
HIV.
As part of the protocol for the multi-center study, all patients will receive an identical combination of AIDS drugs including a protease
inhibitor. Patients in the Reticulose arm of the study will receive the combination therapy plus Reticulose. Reticulose, a non-toxic
peptide-nucleic acid, stimulates the cytocidal (Th-1) arm of the immune system and internal cellular production of cytokines. Patients in the
study will be monitored for viral load as well as immune response parameters such as CD4 and CD8 cell counts.
ADVR, located in Yonkers, N.Y., is a biotechnology company specializing in the development of peptide nucleic acids (PNAs) for
pharmaceutical use. ADVR is seeking to develop Reticulose as an affordable, broad-spectrum treatment for a variety of viral infections and
autoimmune diseases.
NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical
development, regulatory approvals, including applications to the FDA, product commercialization and other risks described from time to
time in the SEC reports filed by ADVR. RETICULOSE has not been approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. |
